INJECTABLE DRUG DELIVERY MARKET ANALYSIS

Injectable Drug Delivery Market - Global Forecast to 2026, by Device Type (Prefilled Syringes, Auto Injectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

Published In : Jun 2019
Code : CMI2768
Pages :262
Formats :
Excel and PDF
Industry : Medical Devices

Market Challenges And Opportunities

Increasing prevalence of chronic diseases such as diabetes and anaphylaxis is expected to propel growth of the global injectable drug delivery market

Increasing prevalence of chronic diseases such as diabetes and other diseases is expected to drive the market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to World Health Organization (WHO) 2018 factsheet, around 8.5% adults aged 18 years and above had diabetes in 2014 globally.

Moreover, the market players are focused on product development and launch of injectors, which is expected to propel growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received the FDA approval.